[go: up one dir, main page]

SI0969846T2 - Sestavki in postopki za zniževanje očesne hipertenzije - Google Patents

Sestavki in postopki za zniževanje očesne hipertenzije

Info

Publication number
SI0969846T2
SI0969846T2 SI9830616T SI9830616T SI0969846T2 SI 0969846 T2 SI0969846 T2 SI 0969846T2 SI 9830616 T SI9830616 T SI 9830616T SI 9830616 T SI9830616 T SI 9830616T SI 0969846 T2 SI0969846 T2 SI 0969846T2
Authority
SI
Slovenia
Prior art keywords
compositions
methods
ocular hypertension
reducing ocular
reducing
Prior art date
Application number
SI9830616T
Other languages
English (en)
Other versions
SI0969846T1 (sl
Inventor
Kenneth Warren Reed
Shau-Fong Yen
Mary Sou
Regina Flinn Peacock
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI0969846(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI0969846T1 publication Critical patent/SI0969846T1/sl
Publication of SI0969846T2 publication Critical patent/SI0969846T2/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI9830616T 1997-03-17 1998-03-13 Sestavki in postopki za zniževanje očesne hipertenzije SI0969846T2 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17
PCT/EP1998/001483 WO1998041208A1 (en) 1997-03-17 1998-03-13 Compositions and methods for reducing ocular hypertension

Publications (2)

Publication Number Publication Date
SI0969846T1 SI0969846T1 (sl) 2004-06-30
SI0969846T2 true SI0969846T2 (sl) 2010-12-31

Family

ID=38729083

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9830616T SI0969846T2 (sl) 1997-03-17 1998-03-13 Sestavki in postopki za zniževanje očesne hipertenzije

Country Status (32)

Country Link
EP (1) EP0969846B2 (sl)
JP (2) JP4920124B2 (sl)
KR (1) KR100555818B1 (sl)
CN (1) CN1236775C (sl)
AR (2) AR002194A1 (sl)
AT (1) ATE257385T1 (sl)
AU (1) AU738781B2 (sl)
BR (2) BRPI9816218B1 (sl)
CA (1) CA2280089C (sl)
CL (1) CL2009001870A1 (sl)
CO (1) CO4940427A1 (sl)
CY (1) CY2526B1 (sl)
CZ (1) CZ299833B6 (sl)
DE (1) DE69820997T3 (sl)
DK (1) DK0969846T4 (sl)
EE (1) EE04091B1 (sl)
ES (1) ES2214706T5 (sl)
HU (1) HU228896B1 (sl)
ID (1) ID22389A (sl)
IL (1) IL131041A0 (sl)
MY (1) MY122237A (sl)
NO (1) NO327713B1 (sl)
NZ (1) NZ337322A (sl)
PE (1) PE61899A1 (sl)
PL (1) PL197509B1 (sl)
PT (1) PT969846E (sl)
RU (1) RU2197970C2 (sl)
SI (1) SI0969846T2 (sl)
TW (1) TW527187B (sl)
UA (1) UA63938C2 (sl)
WO (1) WO1998041208A1 (sl)
ZA (1) ZA982188B (sl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
AU2001286210A1 (en) * 2000-09-13 2002-03-26 Asahi Glass Company, Limited Eye drops
WO2002045748A1 (en) * 2000-12-05 2002-06-13 Sankyo Company, Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
RU2266572C1 (ru) * 2004-03-17 2005-12-20 Российский государственный медицинский университет Способ моделирования злокачественной артериальной гипертонии
CA2558135C (en) * 2004-03-18 2012-08-14 R-Tech Ueno, Ltd. Aqueous composition comprising thiazole derivative
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
DE202005005094U1 (de) * 2005-03-31 2005-07-28 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Ophthalmische Zusammensetzung
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
WO2007015510A1 (ja) * 2005-08-02 2007-02-08 Santen Pharmaceutical Co., Ltd. 熱的に不安定な薬物の分解抑制方法
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
BRPI0708891A2 (pt) * 2006-03-13 2011-06-28 R Tech Ueno Ltd composição aquosa
TWI454286B (zh) * 2006-03-17 2014-10-01 Johnson & Johnson Vision Care 安定氧化性不安定組合物之方法
AU2007313684A1 (en) * 2006-10-31 2008-05-08 Alcon Research, Ltd. PAI-1 binding modulators for the treatment of ocular disorders
EP2123278B1 (en) * 2007-02-07 2013-01-09 Teika Pharmaceutical Co., Ltd. Eye drop preparation comprising latanoprost
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
BRPI0819081A8 (pt) * 2007-10-08 2016-08-30 Fovea Pharmaceuticals Sa Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento
PL2254549T5 (pl) * 2008-03-17 2019-12-31 Alcon Research, Ltd. Wodne kompozycje farmaceutyczne zawierające kompleksy boran-poliole
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
RU2402316C2 (ru) * 2009-01-11 2010-10-27 Пшеничников Виталий Георгиевич Фармацевтическая антиглаукомная композиция
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
WO2012141334A1 (en) * 2011-04-12 2012-10-18 R-Tech Ueno, Ltd. Aqueous ophthalmic composition
US20130029919A1 (en) * 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
EP2787969B1 (en) 2011-12-07 2021-09-29 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
JP6768653B2 (ja) 2014-11-25 2020-10-14 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 安定したオメガ−３眼科用組成物
EP3852608A4 (en) * 2018-09-21 2022-09-28 Aufbau Medical Innovations Limited COMPOSITIONS AND METHODS FOR TREATING GLAUCOMA
WO2020210784A1 (en) 2019-04-12 2020-10-15 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2042936C (en) * 1990-05-22 2002-04-30 Ryuji Ueno Treatment of ocular hypertension with a synergistic combination for ophthalmic use
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
AU1427592A (en) * 1991-02-07 1992-09-07 Allergan, Inc. 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f derivatives
CA2166722A1 (en) * 1994-05-06 1995-11-16 Manoj L. Maniar Use of vitamin e tocopheryl derivatives in ophthalmic compositions
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
DE69820997D1 (de) 2004-02-12
WO1998041208A1 (en) 1998-09-24
KR100555818B1 (ko) 2006-03-03
CZ299833B6 (cs) 2008-12-10
AU738781B2 (en) 2001-09-27
MY122237A (en) 2006-04-29
RU2197970C2 (ru) 2003-02-10
JP2010043110A (ja) 2010-02-25
DE69820997T3 (de) 2011-10-06
HUP0002194A2 (hu) 2000-12-28
PL197509B1 (pl) 2008-04-30
TW527187B (en) 2003-04-11
BRPI9816218B1 (pt) 2016-04-12
DK0969846T4 (da) 2010-12-20
ES2214706T3 (es) 2004-09-16
KR20000076330A (ko) 2000-12-26
EE04091B1 (et) 2003-08-15
CN1249687A (zh) 2000-04-05
ZA982188B (en) 1998-09-17
CN1236775C (zh) 2006-01-18
NO994481L (no) 1999-09-16
PT969846E (pt) 2004-05-31
CA2280089A1 (en) 1998-09-24
EE9900410A (et) 2000-04-17
PE61899A1 (es) 1999-06-30
ID22389A (id) 1999-10-07
EP0969846B2 (en) 2010-08-25
DK0969846T3 (da) 2004-04-13
DE69820997T2 (de) 2004-12-09
CL2009001870A1 (es) 2010-01-22
UA63938C2 (uk) 2004-02-16
PL335168A1 (en) 2000-04-10
AU7035398A (en) 1998-10-12
ES2214706T5 (es) 2011-02-02
HUP0002194A3 (en) 2012-08-28
ATE257385T1 (de) 2004-01-15
EP0969846A1 (en) 2000-01-12
NZ337322A (en) 2001-05-25
CY2526B1 (en) 2006-02-08
CZ325799A3 (cs) 2000-01-12
BR9808016A (pt) 2000-03-08
HK1026841A1 (en) 2000-12-29
CO4940427A1 (es) 2000-07-24
JP4920124B2 (ja) 2012-04-18
AR011192A1 (es) 2000-08-02
NO327713B1 (no) 2009-09-14
NO994481D0 (no) 1999-09-16
EP0969846B1 (en) 2004-01-07
AR002194A1 (es) 1998-01-07
SI0969846T1 (sl) 2004-06-30
JP2001515502A (ja) 2001-09-18
CA2280089C (en) 2009-03-03
HU228896B1 (en) 2013-06-28
IL131041A0 (en) 2001-01-28

Similar Documents

Publication Publication Date Title
CY2526B1 (en) Compositions and methods for reducing ocular hypertension
AU3767097A (en) Shampoo compositions and method
ZA958028B (en) Compositions and methods for treatig mast-cell mediated conditions
AU8693098A (en) Compositions and methods for treating diabetes
AU9214398A (en) Compositions and methods for treating water
ZA989399B (en) Method and composition
IL133784A0 (en) Dolastatin 15 derivatives
AU2349399A (en) R-lansoprazole compositions and methods
ZA989398B (en) Method and composition (l)
EP1056457A4 (en) S-LANSOPRAZOLE COMPOSITIONS AND METHODS OF USE
AU2664797A (en) Wnt receptor compositions and methods
GB9624501D0 (en) Insecticial compositions and method
EP1073333A4 (en) S-RABEPRAZOL COMPOSITIONS AND METHODS
AUPO982097A0 (en) Methods and compositions for use therein
AU9393798A (en) Genetic compositions and methods
AU5546298A (en) Methods and compositions for preventing autoimmune disease
EP1073332A4 (en) R-RABEPRAZOL COMPOSITIONS AND METHODS
AU3900499A (en) (+)-hydroxyrisperidone compositions and methods
AU7287798A (en) Compositions and methods for bioremediation
AU7799898A (en) Compositions and methods for treating glaucoma
AU9105498A (en) Novel compositions and methods for controlling nematodes
AU9474898A (en) Methods and compositions for diagnosing and treating malaria
GB9719842D0 (en) Ophthalmic compositions for treating ocular hypertension
GB9717153D0 (en) Eyedrop composition
GB9721425D0 (en) Composition and method